These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8176096)

  • 1. Ischemia enhances use-dependent sodium channel blockade by pilsicainide, a class IC antiarrhythmic agent.
    Sadanaga T; Ogawa S
    J Am Coll Cardiol; 1994 May; 23(6):1378-81. PubMed ID: 8176096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Class IC antiarrhythmic drugs, flecainide and pilsicainide, produce ST segment elevation simulating inferior myocardial ischemia.
    Nakamura W; Segawa K; Ito H; Tanaka S; Yoshimoto N
    J Cardiovasc Electrophysiol; 1998 Aug; 9(8):855-8. PubMed ID: 9727664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ST segment elevation in the right precordial leads following administration of class Ic antiarrhythmic drugs.
    Yasuda M; Nakazato Y; Yamashita H; Sekita G; Kawano Y; Mineda Y; Nakazato K; Tokano T; Sumiyoshi M; Nakata Y
    Heart; 2001 Jan; 85(1):E3. PubMed ID: 11119481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of the use-dependent QRS prolongation and the reverse use-dependent QT prolongation of class I and class III antiarrhythmic agents and their value in predicting efficacy.
    Sadanaga T; Ogawa S; Okada Y; Tsutsumi N; Iwanaga S; Yoshikawa T; Akaishi M; Handa S
    Am Heart J; 1993 Jul; 126(1):114-21. PubMed ID: 8391748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amplification of flecainide-induced ventricular conduction slowing by exercise. A potentially significant clinical consequence of use-dependent sodium channel blockade.
    Ranger S; Talajic M; Lemery R; Roy D; Nattel S
    Circulation; 1989 May; 79(5):1000-6. PubMed ID: 2540920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Syncope in patients with atrial flutter during treatment with class Ic antiarrhythmic drugs.
    Kawabata M; Hirao K; Horikawa T; Suzuki K; Motokawa K; Suzuki F; Azegami K; Hiejima K
    J Electrocardiol; 2001 Jan; 34(1):65-72. PubMed ID: 11239374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and initial characteristics of pilsicainide-induced ventricular arrhythmias in patients with Brugada syndrome.
    Chinushi M; Komura S; Izumi D; Furushima H; Tanabe Y; Washizuka T; Aizawa Y
    Pacing Clin Electrophysiol; 2007 May; 30(5):662-71. PubMed ID: 17461877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics of use-dependent ventricular conduction slowing by antiarrhythmic drugs in humans.
    Ranger S; Talajic M; Lemery R; Roy D; Villemaire C; Nattel S
    Circulation; 1991 Jun; 83(6):1987-94. PubMed ID: 2040051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ventricular arrhythmia induced by sodium channel blocker in patients with Brugada syndrome.
    Morita H; Morita ST; Nagase S; Banba K; Nishii N; Tani Y; Watanabe A; Nakamura K; Kusano KF; Emori T; Matsubara H; Hina K; Kita T; Ohe T
    J Am Coll Cardiol; 2003 Nov; 42(9):1624-31. PubMed ID: 14607450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proarrhythmic response to sodium channel blockade. Theoretical model and numerical experiments.
    Starmer CF; Lastra AA; Nesterenko VV; Grant AO
    Circulation; 1991 Sep; 84(3):1364-77. PubMed ID: 1653123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiation of the electrophysiological effects on the atrial myocardium between the pure Na channel blocker, pilsicainide, and flecainide.
    Kanemoto M; Shimizu A; Yamagata T; Esato M; Ueyama T; Yoshiga Y; Kakugawa H; Kametani R; Inoue N; Sawa A; Matsuzaki M
    Cardiovasc Drugs Ther; 2004 Jul; 18(4):295-303. PubMed ID: 15367827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three elderly cases with Brugada-type electrocardiographic pattern unmasked by pilsicainide at the toxic level.
    Hiasa G; Okayama H; Nishimura K; Sumimoto T
    Intern Med; 2005 Jan; 44(1):55-9. PubMed ID: 15704664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic monitoring of class I antiarrhythmic agents using high-resolution electrocardiography instead of blood samples.
    Sutovsky I; Katoh T; Takayama H; Ono T; Takano T
    Circ J; 2003 Mar; 67(3):195-8. PubMed ID: 12604865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ischemic modulation of vulnerable period and the effects of pharmacological treatment of ischemia-induced arrhythmias: a simulation study.
    Cimponeriu A; Starmer CF; Bezerianos A
    IEEE Trans Biomed Eng; 2003 Feb; 50(2):168-77. PubMed ID: 12665030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antiarrhythmic effects of pilsicainide hydrochloride and effects on cardiac function and ECG in dogs: comparison with disopyramide].
    Hidaka T; Inoue T; Komoriya K; Hayashi Y; Inomata N
    Nihon Yakurigaku Zasshi; 2000 May; 115(5):295-308. PubMed ID: 10872181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The rise time of the monophasic action potential--a new index of local use-dependent conductivity by sodium channel blockers in human myocardium.
    Shinozaki T; Satoh S; Miura M; Iwabuchi K; Takeuchi M; Suzuki S; Baba S; Katoh H; Funakoshi M; Keitoku M; Watanabe J; Ishide N; Shirato K
    Jpn Circ J; 1997 Dec; 61(12):979-87. PubMed ID: 9412861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic and pharmacodynamic analysis of a class IC antiarrhythmic, pilsicainide, in patients with cardiac arrhythmias.
    Ogawa R; Kishi R; Mihara K; Takahashi H; Takagi A; Matsumoto N; Masuhara K; Nakazawa K; Miyake F; Kobayashi S; Echizen H
    J Clin Pharmacol; 2006 Jan; 46(1):59-68. PubMed ID: 16397285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrophysiologic and hemodynamic effects of a single oral dose of pilsicainide hydrochloride, a new class 1c antiarrhythmic agent.
    Ino T; Atarashi H; Kuruma A; Onodera T; Saitoh H; Hayakawa H
    J Cardiovasc Pharmacol; 1998 Jan; 31(1):157-64. PubMed ID: 9456290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram.
    Morganroth J; Horowitz LN
    Am J Cardiol; 1984 Feb; 53(5):89B-94B. PubMed ID: 6695821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A possible involvement of sodium channel blockade of class-I-type antiarrhythmic agents in postischemic contractile recovery of isolated, perfused hearts.
    Takeo S; Tanonaka K; Hayashi M; Yamamoto K; Liu JX; Kamiyama T; Yamaguchi N; Miura A; Natsukawa T
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1403-9. PubMed ID: 7791114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.